A risk-adjusted evaluation of the impact of neoadjuvant therapy on pancreatic fistula development after pancreatoduodenectomy
Bibliographic record
Abstract
BACKGROUND: Most patients undergoing pancreatoduodenectomy after neoadjuvant therapy for periampullary malignancies have pancreatic adenocarcinoma, a known protective factor against postoperative pancreatic fistula. Accordingly, the perceived lower postoperative rates of pancreatic fistula after neoadjuvant therapy might result from selection bias toward a lower-risk population. Accurate evaluation of neoadjuvant therapy effects requires adjustment for risk. METHODS: Consecutive patients who underwent pancreatoduodenectomy from 2015 to 2022 for all periampullary malignancies were studied at 4 international specialty units. Risk adjustment used the original and alternative Fistula Risk Scores and multivariable analysis. RESULTS: Of 2,240 patients, 80.5% had pancreatic adenocarcinoma; 19.5% had other periampullary malignancies. Neoadjuvant therapy was applied in 39.2%, and patients with pancreatic adenocarcinoma received neoadjuvant therapy more often than those with nonpancreatic ductal adenocarcinoma (47.6% vs. 4.3%, P < .001). Postoperative pancreatic fistula occurred in 289 patients (12.9%), more commonly after upfront resection (15.1%) versus neoadjuvant therapy (9.5%), P < .001. Rates of postoperative pancreatic fistula after neoadjuvant therapy (vs upfront resection) were significantly lower in the setting of pancreatic adenocarcinoma (9.1% vs 12.8%, P = .015), but not in nonpancreatic ductal adenocarcinoma malignancies (26.3% vs 20.3%, P = .73); this is despite patients with pancreatic ductal adenocarcinoma receiving neoadjuvant therapy having a significantly greater median Fistula Risk Score than those patients with pancreatic ductal adenocarcinoma receiving upfront resection (3 vs 2, P < .001). The protection of neoadjuvant therapy (vs upfront resection) was insignificant with blood loss >700 mL (12.8% vs 18.8%, P = .17). Concurrent radiotherapy did not decrease postoperative pancreatic fistula beyond chemotherapy alone (9.9% vs 8.9%, P = .77). Multivariable analysis confirmed a protective association between neoadjuvant therapy and postoperative pancreatic fistula (odds ratio, 0.51; 95% confidence interval, 0.36-0.70, P < .001) for pancreatic adenocarcinoma. CONCLUSION: In the setting of pancreatic adenocarcinoma, neoadjuvant therapy appears to reduce postoperative pancreatic fistula, with reductions significant only with low blood loss. Furthermore, neoadjuvant radiotherapy did not provide added mitigation in this series.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.003 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".